The FDA has approved Foundayo (orforglipron), Eli Lilly's daily oral GLP-1 pill, for adults with obesity and Type 2 diabetes, aiding weight loss and blood sugar control.2
Eli Lilly anticipated US FDA approval for orforglipron by March 2026, as stated by its CEO.1
This approval positions Lilly's oral drug as a competitive answer to Novo Nordisk's GLP-1 offerings in the obesity treatment market.12
Sources:
1. https://hot96.com/2025/11/06/eli-lilly-expects-us-fda-approval-for-oral-obesity-drug-in-march-2026/
2. https://www.newswise.com/articles/fda-approves-daily-oral-glp-1-pill-foundayo-orforglipron-interviews-available